Clinical Trials

263 enrolled 2 FDA

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06137144 2026-04-21

PRIMAVERA

161 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT03932331 2026-04-20

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05189093 2026-04-20

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

48 enrolled

Lymphoma

NCT03960840 2026-04-17

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

217 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05294731 2026-04-17

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

146 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05475925 2026-04-17

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

DermatologicLymphoidOther hematologic neoplasm

200 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05826535 2026-04-17

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

270 enrolled

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT07302347 2026-04-17

MK-3475-G21

20 enrolled

DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT07496229 2026-04-17

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

165 enrolled

Lymphoma, T-Cell

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

152 enrolled

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03934372 2026-04-16

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

70 enrolled

Blast Crisis, Leukemia, Lymphoma, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04521231 2026-04-16

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

281 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04329728 2026-04-15

OPAL

144 enrolled

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06634589 2026-04-15

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT04811560 2026-04-14

cAMeLot-1

420 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06088654 2026-04-14

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Terminated

23 enrolled

Lymphoma, Non-Hodgkin

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

Lymphoma, Non-Hodgkin

NCT04623541 2026-04-13

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05421663 2026-04-13

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

439 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06395103 2026-04-13

MK-9999-01A

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-04-13

Soundtrack-E

408 enrolled

Phase 1/2 Not yet recruiting

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07523555 2026-04-13

ADAPT-HEM

LymphoidMyeloidOther hematologic neoplasmPlasma cell

96 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02625480 2026-04-09

ZUMA-4

95 enrolled

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, B-Cell

NCT07519772 2026-04-09

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

200 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03625037 2026-04-08

EPCORE™ NHL-1

666 enrolled 4 FDA

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04404660 2026-04-08

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

153 enrolled 2 FDA

Burkitt Lymphoma, Recurrence

NCT04542824 2026-04-08

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

211 enrolled

Lymphoma, Non-Hodgkin

NCT06035497 2026-04-06

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

85 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT07109219 2026-04-06

ALLight

83 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03075696 2026-04-03

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 2 FDA

Lymphoma, Non-Hodgkin

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT06492304 2026-04-03

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

12 enrolled

Leukemia, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT07123454 2026-04-03

Lumi-NHL

91 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT07284433 2026-04-02

QUADvance

178 enrolled

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07059650 2026-04-01

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

150 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05765812 2026-03-30

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

116 enrolled

CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT06533579 2026-03-30

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

32 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07134088 2026-03-30

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05896163 2026-03-27

MAPtivate-6

30 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06542250 2026-03-27

TITANium

174 enrolled

Lymphoma, Follicular, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02586857 2026-03-25

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

CNSLymphoidOther hematologic neoplasm

24 enrolled 10 charts

Glioblastoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

GynecologicHead & NeckLymphoid

253 enrolled

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

237 enrolled

Lymphoma, Follicular

NCT04065399 2026-03-18

AUGMENT-101

447 enrolled 4 FDA